ONWARD Support Program Patient Terms of Service

The ONWARD Support Program (“Program”) offers support to patients prescribed ZILBRYSQ and RYSTIGGO. The ONWARD Support Program provides patient support through injection training (ZILBRYSQ), infusion services (RYSTIGGO), phone nurse support, medication reminders and other educational support.

The Program will be delivered subject to these terms of service. By enrolling in the Program, you agree to these terms of service on your own behalf.

The Administrator will facilitate the provision of services under the Program. 

Administration: 

  1. The Program is sponsored by UCB Pharmaceuticals Australia Pty Limited ABN 48 005 799 (UCB) and is administered by an authorised third-party provider nominated by Company (Administrator).

  2. The Administrator is Medical Safety Systems Corporate Pty Ltd trading as “RxMx Australia” ABN 89 608 630 931 (RxMx) however Company may replace RxMx with another Administrator and will notify you of this.

  3. The Administrator will facilitate the provision of communications for the Program, including all phone calls, mail, emails and SMS.

    Eligibility: 

  4. Only Australian residents prescribed ZILBRYSQ are eligible to enrol in the Program, provided they meet the eligibility criteria set out in the Program materials or otherwise notified by Company.

  5. Additional eligibility criteria are included in Program materials or may be notified to you by Company.

     Enrolment: 

  6. If you are enrolled by your treating specialist, she/he will provide your relevant contact details (e.g. email address, telephone number) to Administrators, who will contact you to complete your enrolment. They will also receive an update as to the progress of treatment on ZILBRYSQ via the Portal.

  7. The Portal is a secure password protected portal, that is only available to your treating specialist, additional users nominated by your treating specialist (e.g. clinic nurses, clinic administrators or other authorised personnel), the Administrator and other nominated parties providing information technology services accessed via ucbonward.com.au.

  8. You also consent to the collection, storage, use and disclosure of your, or your child’s, personal information and other matters set out in the Administrator’s privacy policy, available at https://rxmxcorp.com/services-privacy/, Program Privacy Statement and Patient Safety Statement below. UCB Pharmaceuticals Australia Pty Limited’s Privacy Policy is available from: Privacy policy | UCB Australia.

  9. Your enrolment in the Program will depend on the services you have elected to receive, subject to these terms of service.

  10. Once enrolled in the Program, you may opt out, or opt your child out of any aspects, or entirely out of the Program, by contacting the program via email at support@ucbonward.com.au or via phone on 1800 669 272

  11. If you opt out of the Program, the Administrator may continue to hold personal information


    Duration of the Program  

  12. Your enrolment will immediately cease if you: (i) discontinue treatment on ZILBRYSQ (ii) you opt-out from the Program, or (iii) Company discontinues the Program. 

    Services  

  13. Under the Program, You may opt in to receive a range of services as outlined below: 

    a. Coordination of Patient Injection Training for ZILBRYSQ patients 

    b. Coordination of Patient Infusions for RYSTIGGO patients 

    c. Medication delivery service 

    d. Telephone support line – The Administrator may arrange for a support nurse to contact your doctor by telephone to discuss your treatment with ZILBRYSQ or RYSTIGGO . You may also make toll-free inbound calls to a support nurse by phoning 1800 669 272. 

    e. Patient smartphone application (Patient App) – You, following acceptance of the Patient Support Program Terms of Service will receive user access to the Patient App. The Patient App will provide access to your personalised dose record, useful information regarding treatment with ZILBRYSQ or RYSTIGGO, upcoming appointments for consultations or tests and useful contacts. You may also delegate access to the Patient App to a nominated carer. 

    f. Reminder service – a service where you receive medication reminders via email, SMS or push notifications via the app. 

  14. You are only permitted to use these services while you remain a patient of a treating specialist that is participating in this Program. If you cease treatment with a participant specialist, you will not qualify for services unless you become a patient of another participant specialist. 

  15. Please note the services are designed to support the prescribing advice of your treating specialist. The Program is not intended to replace or affect the advice of your treating specialist or any other healthcare professional. 

    Variations or termination and no liability:  

  16. The Company may at any time:

    a. cease funding or terminate the Program for any reason; 

    b. terminate your treating specialist’s participation in the Program; 

    c. include additional services as part of the Program; or 

    d. vary or discontinue services offered under the Program. 

  17. The Company and the Administrator will not bear any liability resulting from the cessation, termination or variation under clause 18. 

  18. To the fullest extent permitted by law, the Company and the Administrator will not be liable for any direct or indirect loss or damage suffered by you or your child because of the Program, including in connection with reliance on the content or on a function of the Portal or any App, use of or inability to use the Portal or any App, or any failure to perform a function or errors and omissions in the content of the Portal or any App. 

    Disclaimer of warranties:

  19. The Program software is provided on an “as is” and “as available” basis. The Company provides no warranties, representations or guarantees about the content on the Program software. The Company disclaims any warranties regarding merchantability, reliability, timeliness, accuracy, completeness, availability and/or performance of the Portal and any App. 

    Use of Program software: 

  20. The Program software is not a medical device. It is intended for informational and educational use only. 

  21. Information accessed via the software is not intended to offer personalised medical diagnosis or patient-specific treatment advice. It should not be used as a basis for any diagnosis, monitoring, management or treatment of diseases or any other medical condition. 

  22. All software included in the Program is owned by the Administrator and was developed in collaboration with Company. You are granted a non-exclusive license to download, install, access and use the software solely in relation to the services you receive under the Program. You must not use the software for any purpose other than as expressly permitted under these terms of service. You do not acquire ownership of any intellectual property rights or any other commercial benefits in connection with your use of the software. 

  23. When using the software you are responsible for:
    a. ensuring that you are using the latest available version; 

    b. any damage to your devices, and any loss or corruption of information that you store in the devices that results from the use of the software or the interaction of the software with other applications, data or programs that you may download or use; and 

    c. maintaining the physical security of your devices and integrity of your data. 

  24. You must not:
    d. modify, edit, improve, resell, reverse engineer, change or otherwise interfere with the operation of the software in any way; 

    e. engage in systematic copying and widespread distribution of content in the software to the public; or 

    f. violate these terms of service 

  25. Because the Company has no control over and does not endorse the content of any websites to which the Program software may be linked, you agree that your access to such other websites is at your own risk. Company accepts no liability for the accuracy or legality of the content on third party sites. Company accepts no liability regarding the third party’s privacy practices. 

    Disclaimer of warranties:

  26. You should speak to your treating specialist if you have any questions or concerns relating to your treatment with ZILBRYSQ or RYSTIGGO. 

  27. You may also refer to the Consumer Medicines Information for ZILBRYSQ here: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-CMI-02459-1 


    Applicable law 

  28. These Terms of Service shall be governed by the laws of New South Wales, Australia.